» Articles » PMID: 35931612

High Endothelial Venules As Potential Gateways for Therapeutics

Overview
Journal Trends Immunol
Date 2022 Aug 5
PMID 35931612
Authors
Affiliations
Soon will be listed here.
Abstract

High endothelial venules (HEVs) are specialized blood vessels that support the migration of lymphocytes from the bloodstream into lymph nodes (LNs). They are also formed ectopically in mammalian organs affected by chronic inflammation and cancer. The recent arrival of immunotherapy at the forefront of many cancer treatment regimens could boost a crucial role for HEVs as gateways for the treatment of cancer. In this review, we describe the microanatomical and biochemical characteristics of HEVs, mechanisms of formation of newly made HEVs, immunotherapies potentially dependent on HEV-mediated T cell homing to tumors, and finally, how HEV-targeted therapies might be used as a complementary approach to potentially shape the therapeutic landscape for the treatment of cancer and immune-mediated diseases.

Citing Articles

Single-cell transcriptomic atlas of different endometriosis indicating that an interaction between endometriosis-associated mesothelial cells (EAMCs) and ectopic stromal cells may influence progesterone resistance.

Hou S, Zhang J, Zhang Z, Qu H, Li S, Jiang Y Clin Transl Med. 2025; 15(2):e70216.

PMID: 39968688 PMC: 11836620. DOI: 10.1002/ctm2.70216.


Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers.

Xu Q, Shao D Front Immunol. 2024; 15:1487610.

PMID: 39691707 PMC: 11649667. DOI: 10.3389/fimmu.2024.1487610.


Clarification of a unique mucosal vaccination route for improved systemic and mucosal immune response in broiler.

Akter R, Masum M, Biswas S, Rubel M, Sarkar S, Islam M Heliyon. 2024; 10(20):e39621.

PMID: 39497952 PMC: 11532882. DOI: 10.1016/j.heliyon.2024.e39621.


Tertiary Lymphoid Structures in Microorganism-Related Cancer.

Deng S, Yang X, He L, Hou Y, Meng H Cancers (Basel). 2024; 16(20).

PMID: 39456558 PMC: 11505735. DOI: 10.3390/cancers16203464.


Lymphatic system regulation of anti-cancer immunity and metastasis.

Lei P, Fraser C, Jones D, Ubellacker J, Padera T Front Immunol. 2024; 15:1449291.

PMID: 39211044 PMC: 11357954. DOI: 10.3389/fimmu.2024.1449291.


References
1.
Kimura N, Mitsuoka C, Kanamori A, Hiraiwa N, Uchimura K, Muramatsu T . Reconstitution of functional L-selectin ligands on a cultured human endothelial cell line by cotransfection of alpha1-->3 fucosyltransferase VII and newly cloned GlcNAcbeta:6-sulfotransferase cDNA. Proc Natl Acad Sci U S A. 1999; 96(8):4530-5. PMC: 16366. DOI: 10.1073/pnas.96.8.4530. View

2.
Panowski S, Bhakta S, Raab H, Polakis P, Junutula J . Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014; 6(1):34-45. PMC: 3929453. DOI: 10.4161/mabs.27022. View

3.
Liu M, Guo F . Recent updates on cancer immunotherapy. Precis Clin Med. 2019; 1(2):65-74. PMC: 6333045. DOI: 10.1093/pcmedi/pby011. View

4.
Toppila S, Paavonen T, Nieminen M, Hayry P, Renkonen R . Endothelial L-selectin ligands are likely to recruit lymphocytes into rejecting human heart transplants. Am J Pathol. 1999; 155(4):1303-10. PMC: 1867005. DOI: 10.1016/S0002-9440(10)65232-7. View

5.
Drayton D, Liao S, Mounzer R, Ruddle N . Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol. 2006; 7(4):344-53. DOI: 10.1038/ni1330. View